A Phase 1 interventional study of VERVE-102 in Heterozygous Familial Hypercholesterolemia and Premature Coronary Heart Disease, sponsored by Verve Therapeutics, Inc.. Recruiting at 27 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Verve Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
This study's planned enrollment of 85 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Browse Hyperlipoproteinemia Type II studies →Verve Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
First submitted before Verve Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Participants will receive a single dose of VERVE-102.
Drug: VERVE-102
Intravenous (IV) infusion
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: up to Day 365
Evaluation of maximum observed concentration (Cmax)
Time frame: up to Day 365
Evaluation of time to maximum observed concentration (tmax)
Time frame: up to Day 365
Evaluation of terminal elimination half-life (t1/2)
Time frame: up to Day 365
Percent and absolute change from baseline in plasma PCSK9 concentration
Time frame: up to Day 365
Percent and absolute change from baseline in LDL-C
Time frame: up to Day 365
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →